Low plasma renin activity and high aldosterone/renin ratio are associated with untreated isolated systolic hypertension

References

• Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, . Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003–1010.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, .; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289: 2560–2572.
   PubMed Web of Science ®Google Scholar
• Lakatta EG. Central arterial aging and the epidemic of systolic hypertension and atherosclerosis. J Am Soc Hypertens. 2007;1:302–340.
   Google Scholar
• Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med. 2007;357:789–796.
   PubMed Web of Science ®Google Scholar
• Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, . Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens. 1999;13:569–592.
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the systolic hypertension in the elderly program. JAMA. 1991;265:3255–3265.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, . Randomised doubleųblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–764.
   PubMed Web of Science ®Google Scholar
• Mahmud A, Feely J. Arterial stiffness and the renin– angiotensin–aldosterone system. J Renin Angiotensin Aldosterone Syst. 2004;5:102–108.
   PubMed Web of Science ®Google Scholar
• Mohamed MA, Weir MR. Renin angiotensin system inhibition in the older person: A review. Clin Geriatr Med. 2009;25: 245–257.
   Google Scholar
• Kithas PA, Supiano MA. Practical recommendations for treatment of hypertension in older patients. Vasc Health Risk Manag. 2010;6:561–569.
   PubMedGoogle Scholar
• Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, . A screening test to identify aldosterone producing adenoma by measuring plasma renin activity: Results in hypertensive patients. Arch Intern Med. 1981;141: 1589–1593.
   PubMed Web of Science ®Google Scholar
• Moneva MH, Gomez-Sanchez CE. Establishing a diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes. 2001;8:124–129.
   Google Scholar
• Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: A clue to efficient treatment. J Hypertens. 2004;22:2217–2226.
   PubMed Web of Science ®Google Scholar
• Tomaschitz A, Maerz W, Pilz S, Ritz E, Scharnagl H, Renner W, . Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol. 2010;55:2171–2180.
   Google Scholar
• Sowers JR, Whaley-Connell A, Epstein M. Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776–783.
   PubMed Web of Science ®Google Scholar
• O’Rourke MF, Frohlich ED. Pulse pressure: Is this a clinically useful risk factor? Hypertension. 1999;34:372–374.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, . Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33–41.
   PubMed Web of Science ®Google Scholar
• Duprez D, De Buyzere M, Rietzschel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep. 2000;2:327–334.
   PubMedGoogle Scholar
• Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: Effects of eplerenone. Circulation. 2002;106:2848–2853.
   PubMed Web of Science ®Google Scholar
• Nehme JA, Lacolley P, Labat C, Challande P, Robidel E, Perret C, . Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure. J Mol Cell Cardiol. 2005;39:511–519.
   Google Scholar
• Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: Focus on blood pressure independent effects. Am J Hypertens. 2003;16:80–86.
   PubMed Web of Science ®Google Scholar
• Park S, Kim JB, Shim CY, Ko YG, Choi D, Jang Y, . The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients. J Hypertens. 2007;25:1279–1283.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, .; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491–1498.
   PubMed Web of Science ®Google Scholar
• White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, . Effects of the selective aldos- terone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41: 1021–1026.
   PubMed Web of Science ®Google Scholar
• He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. The renin–angiotensin system and blood pressure: Differences between blacks and whites. Am J Hypertens. 1999; 12:555–562.
   Google Scholar
• El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, . Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001;37:845–850.
   Google Scholar